A Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 30 Jun 2017
At a glance
- Drugs BMS 986166 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 03 Feb 2017 Planned End Date changed from 1 Aug 2017 to 1 Jul 2017.
- 03 Feb 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Jul 2017.
- 03 Feb 2017 Status changed from not yet recruiting to recruiting.